These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 10353326)

  • 1. Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis.
    Jiang C; Hu F; Li J; Gao G; Guo X
    Breast Cancer Res Treat; 2023 Nov; 202(2):233-244. PubMed ID: 37522998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between prostate-specific antigen, alkaline phosphatase levels, and time-to-tumor shrinkage: understanding the progression of prostate cancer in a longitudinal study.
    Liaqat M; Khan RA; Fischer F; Kamal S
    BMC Urol; 2024 Jul; 24(1):137. PubMed ID: 38956570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasis.
    Ramaswamy G; Rao VR; Krishnamoorthy L; Ramesh G; Gomathy R; Renukadevi D
    Indian J Clin Biochem; 2000 Jul; 15(2):110-3. PubMed ID: 23105250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Ludwigshafen Osteoporosis Screening Questionnaire (LOS Questionnaire): result of the evaluation of anamnestic risk factors in osteoporosis diagnostics].
    Wölfl C; Takur C; Moghaddam AA; Zimmermann G; Hitzler M; Schmidt-Gayk H; Höner B; Grützner PA; Kolios L
    Unfallchirurg; 2013 Feb; 116(2):144-50. PubMed ID: 22170326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Procollagen Type I Aminoterminal Propeptide in Women with Breast Cancer with regard to Metastases.
    Clouth A; Oremek GM
    Patholog Res Int; 2011; 2011():853484. PubMed ID: 22135768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anamnestic risk factor questionnaire as reliable diagnostic instrument for osteoporosis (reduced bone morphogenic density).
    Kolios L; Takur C; Moghaddam A; Hitzler M; Schmidt-Gayk H; Suda AJ; Höner B; Grützner PA; Wölfl C
    BMC Musculoskelet Disord; 2011 Aug; 12():187. PubMed ID: 21849030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.
    Brown DA; Lindmark F; Stattin P; Bälter K; Adami HO; Zheng SL; Xu J; Isaacs WB; Grönberg H; Breit SN; Wiklund FE
    Clin Cancer Res; 2009 Nov; 15(21):6658-64. PubMed ID: 19843661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
    Nakashima J
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
    Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M; Jensen LT; Iversen P
    Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M; Jonas D; Oremek GM
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.